Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

Abstract

Congestive heart failure (CHF) is a serious disease with a poor prognosis. Diabetes is an independent risk factor for CHF, probably in part due to disturbances in myocardial metabolism. Glucagon-like pep-tide-1 (GLP-1) causes glucose-dependent secretion of insulin, improving glycaemic control. In turn, this may improve myocardial metabolism and myocardial function.

The aim of the present study was to assess the feasibility and safety of three days' infusion of recombinant GLP-1 in an open observational study in six patients with type 2 diabetes and CHF. The study included assessment of myocardial function.

There were no major complications of the infusion, and all patients completed the study protocol. Some improvement was observed in glycaemic state, and there was an insignificant trend towards improved myocardial function.

It is concluded that GLP-1 deserves further evaluation in such patients.

Keywords

type 2 diabetes mellitus heart failure glucagon-like peptide-1 GLP-1 left ventricular function

References

1. Stone PH , Muller JE , Hartwell T et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol 1989;14:49–57.

2. Factor SM , Minase T , Sonnenblick EH. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J 1980;99:446–58.

3. Amato L , Paolisso G , Cacciatore F et al. on behalf of the osservatorio geriatrico regione Campania group. Congestive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly. Diabetes Metab 1997;23:213–18.

4. Danielsen R , Nordrehaug JE , Lien E , Vik-Mo FH. Subclinical left ventricular abnormalities in young subjects with long-term type 1 diabetes mellitus detected by digitized M-mode echocardiography. Am J Cardiol 1987;60:143–6.

5. Danielsen R. Factors contributing to left ventricular diastolic dysfunction in long-term type I diabetic subjects. Acta Med Scand 1988;224:249–56.

6. Rodrigues B , McNeill JFH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 1992;26:913–22.

7. Taegtmeyer FH. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 1994;19:59–113.

8. Randle PJ , Garland PB , Hales CN , Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus. Lancet 1963;1:785–9.

9. Perez JE , McGill JB , Santiago JV et al. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 1992;19:1154–62.

10.

10. Hiramatsu K , Ohara N , Shigematsu S et al. Left ventricular filling abnormalities in non-insulin-dependent diabetes mellitus and improvement by a short-term glycemic control. Am J Cardiol 1992;70:1185–9.

11.

11. Gutniak MK , ørskov C , Holst JJ , Ahrén B , Efendid S. Antidiabetogenic effect of Glucagon-Like Peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316–22.

12.

12. Rachman J , Barrow BA , Levy JC , Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997;40:205–11.

13.

13. Ritzel R , ørskov C , Holst JJ , Nauck MA. Pharmacokinetic, insulinotropic, and glucagono-static properties of GLP-1 (7–36 amide) after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995;38:720–5.

14.

14. Byrne MM , Göke B. Human studies with glucagon-like peptide-1: potential of the gut hormone for clinical use. Diabet Med 1996;1:854–60.

15.

15. Nikolaidis LA, Egan JM, Elahi D, Shannon RP. GLP-1 improves myocardial performance in conscious dogs with pacing-induced heart failure. American Heart Association Meeting, 2001 (abstract).